Literature DB >> 6848204

Prognosis in carcinoma of the urinary bladder based upon tissue blood group abh and Thomsen-Friedenreich antigen status and karyotype of the initial tumor.

J L Summers, J S Coon, R M Ward, W H Falor, A W Miller, R S Weinstein.   

Abstract

Several markers of initial bladder carcinomas described recently may be clinically significant predictors of biological behavior of future recurrences. Comparison of the marker systems and assessment of the value of using multiple markers have been difficult, because the various markers have been studied in different patients. In this study, we compared four markers [chromosome mode, marker chromosomes, and expression of the ABH "blood group" antigens and the Thomsen-Friedenreich antigen (using immunoperoxidase or lectin immunoperoxidase methods)] in 39 patients presenting initially with low-stage bladder carcinoma and followed 3 to 11 years or until deep muscle invasion occurred. Each of the markers was significantly related to subsequent recurrences with deep muscle invasion, and each marker system was able to identify those patients with a very low risk of subsequent invasion. For detection of a subpopulation of patients with Grade II carcinomas who were at high risk for development of subsequent invasion, combinations of markers, especially hyperdiploidy and abnormal expression of the Thomsen-Friedenreich antigen, were significantly more effective than any single marker system.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848204

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

2.  A conserved major facilitator superfamily member orchestrates a subset of O-glycosylation to aid macrophage tissue invasion.

Authors:  Katarina Valoskova; Julia Biebl; Marko Roblek; Shamsi Emtenani; Attila Gyoergy; Michaela Misova; Aparna Ratheesh; Patricia Reis-Rodrigues; Kateryna Shkarina; Ida Signe Bohse Larsen; Sergey Y Vakhrushev; Henrik Clausen; Daria E Siekhaus
Journal:  Elife       Date:  2019-03-26       Impact factor: 8.140

3.  Immunohistochemistry of cytokeratin proteins in squamous and transitional cell lesions of the urinary tract.

Authors:  M F Tungekar; K C Gatter; M S Al-Adnani
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

4.  Tn and T blood group precursor antigens are universal, clonal, epithelial cell-adhesive, autoimmunogenic carcinoma (CA) markers.

Authors:  G F Springer
Journal:  Naturwissenschaften       Date:  1983-07

5.  Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies.

Authors:  Y Fradet; N Islam; L Boucher; C Parent-Vaugeois; M Tardif
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

6.  Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma.

Authors:  S M Kheir; S D Bines; J H Vonroenn; S J Soong; M M Urist; J S Coon
Journal:  Ann Surg       Date:  1988-04       Impact factor: 12.969

7.  Do blood groups have effect on prognosis of patients undergoing radical cystectomy?

Authors:  Evren Süer; Cihat Özcan; Ilker Gökçe; Ömer Gülpınar; Cağatay Göğüş; Kadir Türkölmez; Sümer Baltacı; Yaşar Bedük
Journal:  Int Urol Nephrol       Date:  2014-03-28       Impact factor: 2.370

8.  Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody: a possible marker of recurrence.

Authors:  H Ohoka; H Shinomiya; M Yokoyama; K Ochi; M Takeuchi; S Utsumi
Journal:  Urol Res       Date:  1985

9.  Flow cytometric evaluation of Thomsen-Friedenreich antigen on transitional cell cancer using monoclonal antibody.

Authors:  H Oda; T Oda; H Ohoka; M Yokoyama; M Takeuchi
Journal:  Urol Res       Date:  1990

10.  Lung cancer patients' autoimmune responses to Thomsen-Friedenreich (T) antigen: diagnostic utility.

Authors:  W A Fry; G F Springer; P R Desai
Journal:  Klin Wochenschr       Date:  1983-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.